Premium
(‐)‐epigallocatechin‐3‐gallate reduces experimental colon injury in rats by regulating macrophage and mast cell
Author(s) -
Mochizuki Miyako,
Hasegawa Noboru
Publication year - 2010
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.2862
Subject(s) - myeloperoxidase , histamine , mast cell , gallate , colitis , inflammatory bowel disease , chemistry , macrophage , pharmacology , epigallocatechin gallate , immunology , biochemistry , medicine , inflammation , in vitro , antioxidant , polyphenol , disease
The ameliorative effect of (‐)‐epigallocatechin‐3‐gallate (EGCG) on inflammatory bowel disease (IBD) induced by ethanol 2,4,6‐trinitrobenzene sulfonic acid (TNBS) was studied in 7‐week‐old male rats. Intestinal lesions were measured as an increase in myeloperoxidase (MPO) activity in mucosa. The supplementation of EGCG significantly inhibited MPO activity and histamine levels in the distal colon mucosa. The EGCG inhibited macrophage chemotaxis toward N ‐formyl‐ l ‐methionyl‐ l ‐leucyl‐ l ‐phenylalanine in a concentration‐dependent manner. These observations confirmed that EGCG can ameliorate acute experimental colitis by the suppression of mast cells and macrophage activities. Copyright © 2009 John Wiley & Sons, Ltd.